EFFICIENCY OF MULTICOMPONENT THERAPY IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (CLINICAL CASE)
- Autores: Koteshkova O.M1, Molina L.P1
-
Afiliações:
- Edição: Nº 5 (2016)
- Páginas: 66-70
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/288768
- ID: 288768
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Recently, glucagon-like peptide-1 agonists (GPP-1-a) are actively applied in the treatment of type 2 diabetes mellitus (DM2). To assess the effectiveness of exenatide treatment, multicentric international studies were conducted that have proven highly effective addition of the drug to metformin, sulfonylureas, and combinations thereof. A clinical experience of exenatide for the intensification of DM2 treatment, which showed that exenatide can be recommended for DM2 patients with overweight, glycated hemoglobin levels >7%, in case of ineffectiveness of the previous combination therapy.
Texto integral
Sobre autores
O. Koteshkova
Email: koala58@mail.ru
SBHCI Endocrinological Dispensary of Moscow Healthcare Department Doctor of the highest qualification category, Head of the Department of Education and Treatment of Diabetes Mellitus
L. Molina
SBHCI Endocrinological Dispensary of Moscow Healthcare Department
Bibliografia
- Kimmei B., Inzucchi E.M. Oralagents for type 2 diabetes: an update. Clin. Diabetes. 2005; 23(2):64-76.
- Deacon C.F., Mannucci E., AhrenGlycaemic B. efficacy of glucagon like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors as add on therapy to metformin in subjects with type 2 diabetes a review and meta analysis. Diabetes Obes. Metab. 2012;14(8):762-67.
- Gregorio F., Ambrosi F., Manfrini S., et al. Poorly controlled elderly Type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin. Diabetic Medicine. 1999;16( 12):1016-24.
- Hirsch I.B., Bergenstal R.M. A real-worldapproach to insulin therapy in primary care practice. Clin. Diabetes. 2005;23(2):78-86.
- Zhao Y., Campbell C.R., Fonseca V., et al. Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes. Diabetes Care. 2012;35(5): 1126-32.
- American Diabetes Association. Approaches to Glycemic Treatment. Diabetes Care. 2015;38(Suppl. 1):41-8.
- Inzucchi S.E, Bergenstal R.M., Buse J.B., et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38( 1 ): 140-49.
- Дедов И.И., Шестакова М.В. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Сахарный диабет. 2015;18(Suppl. 1): 1-112.
- Викулова О.К., Шестакова М.В. Новые показания к терапии эксенатидом у больных сахарным диабетом 2 типа с ожирением. Diabetes Mellitus. 2010;3:98-104.
- Викулова О.К., Шестакова М.В. Клиническая эффективность миметика инкретинов экзенатида: результаты исследований и показания к применению у больных сахарным диабетом типа 2. Consilium Medicum. 2008;10(9):12-8.
- Nielsen L.L., Young A.A., Parkers D.G. Pharmacology of exenatide ( synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul. Rept. 2004;1177:77-88.
- Buse J.B., Henry R.R., Han J., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27( 11):2628-35.
- De Fronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin- treated patients with type 2 diabetes. Diabetes Care. 2005;28(5): 1092-100.
- Kendall D. M., Riddle C., Rosenstock J., Zhuang D., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (exendin-4) on glycemic control and over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28(5):1083-91.
- Ahren B. Incretin therapy of type 2 diabetes GLP-1 receptor agonists and DPP-4 inhibitors. Eur. Diabet. Nursing. 2013;10:31 -6.
- Cervera A., Wajcberg E., Sriwijitkamol A., Fernandez M., Zuo P., Triplitt C., Musi N., DeFronzo R.A., Cersosimo E. Mechanismofaction of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 2008;294:846-52.
- Umapathysivam M.M., Lee M.Y., Jones K.L., Annink C.E., Cousins C.E., Trahair L. G., Rayner C.K. Comparative effects of prolonged and intermittent stimuiation of the giucagon-iikeрeptide 1 receptor on gastric empty in gandglycemia. Diabetes. 2014;63.785-90.
Arquivos suplementares
